ProxyBio Inc.
ProxyBio is a biotechnology company focused on accelerating drug discovery and personalized medicine through the use of patient-derived organoids and AI-powered analysis. Their three-pronged approach utilizes self-organizing human organoid models to accurately predict drug efficacy and safety, addressing the high failure rates in clinical trials and the lack of personalized therapies. Their ProxyDISCOVERY platform offers high-throughput screening, target validation, lead optimization, and clinical trial support by providing patient-relevant models that mirror tumor biology and functional readouts of drug response. This technology helps partners cut clinical trial failures, saving costs and accelerating time to market, positioning ProxyBio at the forefront of a regulatory shift towards human-relevant drug development.
ProxyBio Inc.
ProxyBio is a biotechnology company focused on accelerating drug discovery and personalized medicine through the use of patient-derived organoids and AI-powered analysis. Their three-pronged approach utilizes self-organizing human organoid models to accurately predict drug efficacy and safety, addressing the high failure rates in clinical trials and the lack of personalized therapies. Their ProxyDISCOVERY platform offers high-throughput screening, target validation, lead optimization, and clinical trial support by providing patient-relevant models that mirror tumor biology and functional readouts of drug response. This technology helps partners cut clinical trial failures, saving costs and accelerating time to market, positioning ProxyBio at the forefront of a regulatory shift towards human-relevant drug development.